Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

"…AGs have played a significant role in clinical practice in recent years.…"

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

"…AGs have played a significant role in clinical practice in recent years.…"

Summary of clinical efficacy of relevant PTSD treatments. حسب Filip Stanicic (17808254)

الموضوعات:

Voxel-based whole-hemisphere analysis shows regional and dose-dependent decrease of microglia. حسب Francesca Catto (21253435)

Forest plot of the second endpoint of the clinical symptom improvement. حسب Jin-Min Gu (17915039)

الموضوعات:

EF-24 induces significant transcriptional changes in K-562 cells. حسب Ajeet P. Singh (22298432)

الموضوعات:

EF-24 treatment significantly reduces cell viability in leukemia cell lines. حسب Ajeet P. Singh (22298432)

الموضوعات:

The flow-diagram for the randomised clinical study. حسب Iva Milinkovic (22331710)

الموضوعات:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. حسب Filip Stanicic (17808254)

الموضوعات: